6 days Ago By ABMN Staff
XTX Topco Ltd increased its position in shares of Puma Biotechnology, Inc. ( NASDAQ:PBYI – Free Report ) by 126.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission.
The firm owned 59,674 shares of the biopharmaceutical company’s stock after buying an additional 33,290 shares during the period. XTX Topco Ltd owned 0.12% of Puma Biotechnology worth $182,000 at the end of the most recent reporting period.
Several other large investors have also modified their holdings of PBYI. Barclays PLC boosted its holdings in Puma Biotechnology by 13.3% in the 4th quarter.
Barclays PLC now owns 88,407 shares of the biopharmaceutical company’s stock valued at $270,000 after purchasing an additional 10,386 shares during the period. Kennedy Capital Management LLC boosted its holdings in Puma Biotechnology by 36.5% in the 4th quarter.
Kennedy Capital Management LLC now owns 809,375 shares of the biopharmaceutical company’s stock valued at $2,469,000 after purchasing an additional 216,329 shares during the period. LSV Asset Management boosted its holdings in Puma Biotechnology by 75.7% in the 4th quarter.
LSV Asset Management now owns 53,400 shares of the biopharmaceutical company’s stock valued at $163,000 after purchasing an additional 23,000 shares during the period. Wells Fargo & Company MN boosted its holdings in Puma Biotechnology by 36.5% in the 4th quarter.
Wells Fargo & Company MN now owns 22,929 shares of the biopharmaceutical company’s stock valued at $70,000 after purchasing an additional 6,126 shares during the period. Finally, Integrated Quantitative Investments LLC bought a new stake in Puma Biotechnology in the 4th quarter valued at $183,000. 61.
29% of the stock is owned by institutional investors. Analyst Ratings Changes A number of analysts have weighed in on PBYI shares. StockNews.
com raised shares of Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a report on Friday. HC Wainwright restated a “buy” rating and issued a $7.00 price objective on shares of Puma Biotechnology in a research note on Friday, February 28th.
Puma Biotechnology Trading Down 0.7 % Shares of PBYI stock opened at $2.98 on Tuesday.
Puma Biotechnology, Inc. has a 52-week low of $2.23 and a 52-week high of $5.
26. The stock has a market cap of $147.84 million, a price-to-earnings ratio of 6.
21 and a beta of 1.34. The company has a debt-to-equity ratio of 0.
46, a quick ratio of 1.40 and a current ratio of 1.42.
The firm has a fifty day moving average of $3.11 and a 200-day moving average of $3.03.
Puma Biotechnology ( NASDAQ:PBYI – Get Free Report ) last announced its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported $0.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.
10 by $0.29. Puma Biotechnology had a net margin of 9.
56% and a return on equity of 41.60%. The company had revenue of $59.
10 million during the quarter, compared to analysts’ expectations of $52.50 million. On average, equities research analysts forecast that Puma Biotechnology, Inc.
will post 0.31 earnings per share for the current fiscal year. Puma Biotechnology Company Profile ( Free Report ) Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.
The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. See Also Want to see what other hedge funds are holding PBYI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Puma Biotechnology, Inc.
( NASDAQ:PBYI – Free Report ). Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter .
.
